Answers are grounded in this paper and cite their sources.
The management of advanced cancers of the larynx and hypopharynx has become increasingly complex as different treatment modalities including surgery, radiation, and chemotherapy have been combined with the goal of improving local disease control and disease-specific survival. A union of 17 comprehensive cancer centers in the United States, the National Comprehensive Cancer Network (NCCN), was formed in 1995 to promote state-of-the-art cancer care. To achieve this goal, multidisciplinary panels of experts from member institutions have created disease-specific practice guidelines for the evaluation and treatment of cancer patients, including head and neck cancers. 47 These guidelines, intended to help clarify and standardize care of patients with head and neck cancers, were based, where possible, on the findings of multicenter randomized, controlled trials. Many decision points in patient management have not been evaluated to date in such trials, however, and therefore data from phase II trials and case series also influenced the treatment guidelines. Although detailed analysis of surgical methods and radiation techniques is beyond the scope of this article, the evolving laryngeal preservation strategies for patients with advanced, resectable hypopharyngeal or laryngeal (including supraglottic and glottic) cancers are reviewed, using the relevant sections of the NCCN practice guidelines as a framework for discussion. Until recently in the United States, the conventional therapy given patients with locally advanced laryngeal (T3 or T4) or hypopharyngeal (T2, T3, or T4) cancers has been total laryngectomy with neck dissection followed by postoperative radiation therapy. 54 Unfortunately, patients treated with laryngectomy suffer a complete loss of voice and sometimes impairment of swallowing function, leading to decreased overall quality of life in many aspects, including nutrition, social functioning, and personal hygiene. These problems motivated the development of laryngeal-preservation approaches. Organ-preservation approaches have included induction chemotherapy followed in responding patients by radiation and primary radiation therapy alone with surgery reserved for treatment failures. After resectable, advanced laryngeal or hypopharyngeal cancer has been diagnosed, patients and their treating physicians must choose among three primary treatment modalities that are currently available. The NCCN practice guidelines present these three options as surgery, induction chemotherapy, or definitive radiation therapy (Figs. 1 , 2 , and 3) . Many factors contribute to the decision-making process, including patient preference, performance status, tumor location and stage, and the treatment practices of the patient's physicians. Recently, the Department of Veterans Affairs (VA) and the European Organization for Research and Treatment of Cancer (EORTC) reported two landmark randomized, controlled trials in patients with advanced, resectable laryngeal or hypopharyngeal cancer. These two large trials compared primary surgical management with a laryngeal preservation approach of induction chemotherapy followed by definitive radiation. The trials demonstrated that overall survival was comparable in the two treatment groups. 16 , 37 Moreover, laryngeal preservation was enjoyed by one half to two thirds of the surviving patients in the chemotherapy plus radiation therapy group but by none of the primary laryngectomy patients at 5 years. Given that data from these two important trials served as a foundation for the critical decision point of choosing primary therapy shown in the NCCN guidelines, an understanding of the treatment algorithms requires careful consideration of the findings in these two trials.
No takes yet. Share an insight, caveat, or question.
Gillison et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: